The metabolic syndrome is highly prevalent in patients with schizophrenia, and is associated with a state of chronic, low-grade inflammation. Schizophrenia is also associated with increased inflammation, including aberrant blood levels of pro-inflammatory cytokines and high-sensitivity C-reactive protein (hsCRP). The purpose of this study is to investigate the relationship between total and differential white blood cell (WBC) counts, hsCRP, and the metabolic syndrome in patients with schizophrenia and related non-affective psychoses. Fifty-nine inpatients and outpatients age 18-70 with non-affective psychotic disorders and 22 controls participated in this cross-sectional study. Subjects had a fasting blood draw between 8 and 9 am for glucose, lipids, total and differential WBC counts, and hsCRP. Vital signs and anthropometric measures were obtained. Patients with non-affective psychosis and the metabolic syndrome had significantly higher total WBC counts, monocytes, and hsCRP levels than patients without the metabolic syndrome (p 6 0.04 for each). In binary logistic regression analyses, after controlling for potential confounding effects of age, race, sex, age at first hospitalization for psychosis, parental history of diabetes, smoking, and psychotropic medications, total WBC count, monocytes, and hsCRP were significant predictors of metabolic syndrome in patients (p 6 0.04 for each). hsCRP was also a significant predictor of increased waist circumference and triglycerides in patients (p 6 0.05 for each). Our findings suggest that measurement of total and differential WBC counts and hsCRP blood levels may be germane to the clinical care of patients with schizophrenia and related disorders, and support an association between inflammation and metabolic disturbance in these patients.
Introduction
The metabolic syndrome is a constellation of metabolic risk factors associated with the development of atherosclerotic cardiovascular disease (Galassi et al., 2006; Grundy et al., 2005) and cardiovascular disease mortality (Galassi et al., 2006) . The metabolic syndrome is common in patients with schizophrenia and related disorders, with a prevalence of 43% -based on American Heart Association criteria (Grundy et al., 2005) -in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE; McEvoy et al., 2005) . Cardiovascular disease is also the leading cause of mortality in patients with schizophrenia and related disorders (Saha et al., 2007) .
The metabolic syndrome is also associated with a state of chronic, low-grade inflammation (Devaraj et al., 2010) . A recent meta-analysis found that high-sensitivity CRP (hsCRP) was an independent predictor of cardiovascular disease (Kaptoge et al., 2010) . Schizophrenia is also associated with increased inflammation, including aberrant blood levels of pro-inflammatory cytokines (Miller et al., 2011) and CRP (Miller et al., 2012) , including studies in patients with first-episode psychosis and minimal exposure to antipsychotics. The adverse metabolic effects of atypical antipsychotics, which increase metabolic syndrome risk, may potentiate aberrant blood levels of inflammatory markers (Beumer et al., 2012) . The efficacy of antipsychotic augmentation with non-steroidal anti-inflammatory agents (NSAIDs) also supports an association between inflammation and the pathophysiology of schizophrenia (Akhondzadeh et al., 2007; Laan et al., 2010; Muller et al., 2002 Muller et al., , 2010 .
Several large population-based samples found that total and differential white blood cell (WBC) counts were associated with metabolic syndrome risk and individual metabolic syndrome criteria (Kim et al., 2008; Lao et al., 2008) . Within schizophrenia, one study found that higher total WBC counts are associated with increased risk of the metabolic syndrome and more severe psychopathology (Fan et al., 2010) . Several studies have also reported significant associations between CRP levels and components of the metabolic
